Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to ... (dianapolis Ind. Lilly provides answers -...)

Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months

Date:9/2/2008

dianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.co.uk

P-LLY

This press release contains forward-looking statements about the safety and efficacy of olanzapine long acting injection (LAI) and reflects Lilly's current beliefs. However, as with any investigational pharmaceutical product, there are substantial risks and uncertainties in the process of research, development, regulatory milestones and commercialization. There is no guarantee that olanzapine LAI will be approved for the treatment of schizophrenia or that if approved, it will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(1) Maxine X. Patel and Anthony S. David. Why aren't depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment (2005) 11: 203-211.

(2) Falkai P., Wobrock T., Lieberman J., Glenthoj B.,Gattaz W.F., Moller H.J. & Wfsbp Task Force On Treatment Guidelines For Schizophrenia. The World Journal of Biological Psychiatry, 2006; 7(1): 5/40

(3) Maxine X. Patel and Anthony S. David. Why aren't depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment (2005) 11: 203-211.

(4) Kane J.M. et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology, Volume 8, Number 1, 1 February 1998, pp. 55-66(12). p. 58.

(5) Maxine X. Patel and Anthony S. David. Why aren't depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment (2005) 11: 203-211.

(6) American Psychiatric Association. Diagno
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
3. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
4. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
5. New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
6. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
7. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
8. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
9. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
10. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

Post Your Comments:

(Date:12/15/2009)... Dec. 15 Varian Medical Systems (NYSE: ... results for first quarter of fiscal year 2010 following ... 2010. The news release will be followed by ... p.m. PT. The news release and a link ... the company website at: www.varian.com/investor . To ...

(Date:12/15/2009)... Calif., Dec. 15 Masimo (Nasdaq: ... Measure-Through Motion and Low Perfusion pulse oximetry, today ... has been awarded the 2009 Frost & Sullivan ... American Patient Monitoring market. According to Frost & ... Mr. Kiani,s "unprecedented ability in understanding customer requirements, ...

(Date:12/15/2009)... Rib-X Pharmaceuticals, Inc., a company focused ... drugs for the treatment of serious multi-drug-resistant infections ... research agreement with Massachusetts General Hospital (MGH). ... collaboration, Dr. David Hooper of MGH will evaluate ... model to determine resistance development and to validate ...

Breaking Medicine Technology:Varian Medical Systems Schedules First Quarter FY2010 News Release and Conference Call 2 Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 2 Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 3 Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 4 Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 5 Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 6 Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2 Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3 American Community Introduces Latitude 28TM 29 Health Plan for Employer Groups in Nebraska 55321 1 American Community Introduces Latitude 28TM 29 Health Plan for Employer Groups in Nebraska 55321 2 NexBio 28R 29 Demonstrates DAS181 28Fludase 28R 29 29 a Broad Spectrum Drug Candidate Inhibits Influenza Viral Infection in Human Lung Tissue 13689 1 NexBio 28R 29 Demonstrates DAS181 28Fludase 28R 29 29 a Broad Spectrum Drug Candidate Inhibits Influenza Viral Infection in Human Lung Tissue 13689 2 NexBio 28R 29 Demonstrates DAS181 28Fludase 28R 29 29 a Broad Spectrum Drug Candidate Inhibits Influenza Viral Infection in Human Lung Tissue 13689 3 NexBio 28R 29 Demonstrates DAS181 28Fludase 28R 29 29 a Broad Spectrum Drug Candidate Inhibits Influenza Viral Infection in Human Lung Tissue 13689 4 SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 13688 1 SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 13688 2 SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 13688 3 SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 13688 4

[0] Varian Medical Systems Schedules First Quarter FY2010 News Release and Conference Call [0] Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award [0] Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital

... INDIANAPOLIS, Nov. 6 Eli Lilly and Company,(NYSE: ... from the National,Committee for Quality Assurance (NCQA) for ... Tools that Empower(TM) Depression Care Management Program is ... driving the standard of,patient care around Major Depressive ...

... FALLS, N.J., Nov. 5 CANTEL MEDICAL,CORP. (NYSE: ... significant,interest from schools for its hand sanitization and ... of MRSA,(Methicillin-resistant Staphylococcus aureus) skin infections. According ... CEO, "We are,in contact with numerous school officials ...

Other Medicine Technology:Lilly Receives NCQA Design Certification for Depression Care Management Program 2 Lilly Receives NCQA Design Certification for Depression Care Management Program 3 Cantel Medical Corp.'s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products 2 Cantel Medical Corp.'s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products 3

Lilly Receives NCQA Design Certification for Depression Care Management Program Cantel Medical Corp.'s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products

(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... the U.S. and its International Trade ... http://www.reportlinker.com/p0167482/In-Vitro-Diagnostic-Substance-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html ,, The newly published ... provides the latest market research on ...

(Date:12/15/2009)... Dec. 15 Reportlinker.com announces ... is available in its catalogue: ,, ... Therapeutics - Market Forecasts to 2015, ... Analysis ,, http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ... author has released its latest research ...

(Date:12/15/2009)... Research shows a direct correlation between ... as building a culture of health improvement can ... to a new white paper from The Vitality ... workplace represents an ideal setting for the delivery ... sustaining a corporate culture of health is a ...

(Date:12/15/2009)... cells may offer a new option to treat about ... amplified signaling of the epidermal growth factor receptor (EGFR), ... Jonsson Comprehensive Cancer Center. , Rapidly dividing cancer cells ... The fatty acids also provide an alternative energy source ... regulating cell signaling, said Dr. Paul Mischel, a professor ...

(Date:12/15/2009)... by The University of Western Ontario reveals that couples ... report higher average measures of happiness and life satisfaction ... roles, category, where each partner,s unpaid work is within ... a growing category that now represents more than 25 ... be in a shared roles model when women have ...

[0] Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition][0] Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs [0] Targeting brain cancer cell metabolism may provide new treatment [0] Couples who do the dishes together stay happier

... get the blues during the course of the winter and ... far more difficult to overcome the seasonal affective disorder (SAD), ... ,Those who suffer from SAD overeat, sleep ... irritability and depression and develop an aversion to social interactions. ...

... In a study it has been revealed that in the ... number of children.// ,This is as per Statistics Canada. ... at a quick pace.,The year 2015 will have number of ... children under the age of 15. ,Also by 2031, ...

... the bacteria responsible for causing tooth decay, are able ... that is considered// vital for the survival of normal ... have revealed that the tooth decay causing bacteria can ... were met with skepticism … because the dogma was ...

... A new blood test that can detect non-small cell lung ... the University of Kentucky. The test is highly accurate// and ... identified by advanced CT scans. ,The University has ... development of a test to detect lung cancer in smokers ...

... and Technology Committee has issued a warning that if a ... a severe shortage of food. // ,The ... on an international level and has asked the Government to ... arise. As staff continue to take leave and supermarket deliveries ...

... is well known how nutritional dense milk is ... and to develop valuable new products with nutraceutical, ... been initiated in The University of Queensland's Institute ... R&D company. Microbial Screening Technologies (MST) has teamed ...

Other Medicine News:

SAD Patients Require Treatment A sharp increased in senior citizens: set to outpace children.Tooth Decay Bacteria Unaffected By Altered Biochemical Pathway New Test For Early Detection of Non-Small Cell Lung Cancer UK Committee Warns on Food Shortages Due to Flu Epidemic The many facets of milk and its health potential

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Cytomegalovirus Antibody, IgG Cytology, Tzanck Smear Cytology, SurePathLiquid-Based Pap Test (AutoCyte PREP System) with Reflex to Human Papillomavirus (HPV) DNA Probe, High Risk Cytology, Pulmonary

Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to ...(dianapolis Ind. Lilly provides answers -...),Health